MyoMed-205 is an inhibitor targeting the activity of MuRF1. MyoMed-205 prevents early diaphragmatic systolic dysfunction and atrop due to unilateral diaphragmatic nerve denervation 12 hours later. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed-205 increases levels of a protein that phosphorylates Akt (ser473), an important signaling molecule for muscle growth and maintenance. MyoMed-205 can be used to study and treat diaphragmatic dysfunction and atrop (DIDD) caused by early apraxia, especially in clinical situations such as diaphragmatic paralysis or mechanical ventilation.
References:
[1]. Ribeiro F, et al. Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrop[J]. International Journal of Molecular Sciences, 2023, 24(4): 3637.